CytRx (CYTR) Cash Flow Statement

Click line-items for a historical chart and %

Net loss	-43.1M
Depreciation and amortization	364.55K
Retirement of fixed assets	9.12K
Non-cash gain on transfer of RXi common stock
Stock option and warrant expense	5.4M
Fair value adjustment on warrant liability	-939.67K
Receivable	4.49M
Interest receivable	28.13K
Prepaid expenses and other current assets	781.01K
Income taxes recoverable
Accounts payable	-3.25M
Accrued expenses and other current liabilities	-4.64M
Net cash used in operating activities
Net proceeds from sale of marketable securities
Proceeds from sale of assets held for sale
Proceeds from sale of unconsolidated subsidiary shares
Purchases of equipment and furnishings	-961.22K
Net cash provided by investing activities
Net proceeds from exercise of stock options
Net cash provided by financing activities
Net increase in cash and cash equivalents	36.61M
Cash and cash equivalents at beginning of period	22.26M
Cash and cash equivalents at end of period	58.88M
Cash received during the period as interest income

Entities mentioned with CYTR

View All Entities